Oral testosterone undecanoate (Andriol) + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypogonadism
Conditions
Hypogonadism, Androgens
Trial Timeline
Nov 1, 2001 → Jul 1, 2004
NCT ID
NCT00434824About Oral testosterone undecanoate (Andriol) + Placebo
Oral testosterone undecanoate (Andriol) + Placebo is a phase 2 stage product being developed by Merck for Hypogonadism. The current trial status is completed. This product is registered under clinical trial identifier NCT00434824. Target conditions include Hypogonadism, Androgens.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00434824 | Phase 2 | Completed |
Competing Products
20 competing products in Hypogonadism